Cantor Fitzgerald analyst Louise Chen initiated coverage of Perspective Therapeutics with an Overweight rating. Perspective Therapeutics has a robust pipeline with multiple near-term data readouts and is a fully integrated radiopharma company advancing potentially best- or first-in-class alpha-particle therapies, the analyst tells investors in a research note. Perspective stands out above the competition where it matters, Cantor argues, adding that positive data for VMT01 could open up a large market opportunity. The stock looks undervalued based on recent M&A activity, the firm adds.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CATX:
- Perspective Therapeutics to Participate at Upcoming May Investor Conferences
- Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results
- Perspective Therapeutics selected by FDA to participate in CDRP program
- Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs
- Perspective Therapeutics price target raised to $1.70 from $1.20 at B. Riley
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue